ArticleJAC-antimicrobial resistance2025
Novel approach in treatment of
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment of melioidosis in cats and dogs: antimicrobial therapy and clinical guidance for Burkholderia pseudomallei infections.Australian veterinary journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Melioidosis, caused by Objectives: To report a novel case of Methods: A 59-year-old man presented with radial osteomyelitis requiring multiple rounds of surgical debridement. Severe allergic reactions to trimethoprim/sulfamethoxazole and ceftazidime, and meropenem-associated leukopenia made traditional therapies unfeasible. Levonadifloxacin was introduced as a salvage therapy, leveraging its efficacy against Conclusions: Levonadifloxacin emerged as the salvage therapy for this patient, achieving significant clinical improvement without relapse after more than 6 months of therapy cessation, despite the life-threatening combination of melioidosis-associated osteomyelitis and antibiotic intolerance. This first reported use of levonadifloxacin in melioidosis underscores its potential as an alternative therapy in such complex infections. Aggressive surgical intervention and tailored antimicrobial strategies remain crucial to overcoming these dual challenges.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.